Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $19.11 in the prior trading day, NovoCure Ltd (NASDAQ: NVCR) closed at $17.04, down -10.83%. In other words, the price has decreased by -$10.83 from its previous closing price. On the day, 2.55 million shares were traded.
Ratios:
Our goal is to gain a better understanding of NVCR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.41 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on December 02, 2024, Upgraded its rating to Outperform and sets its target price to $30 from $18 previously.
On October 16, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $24 to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’25 when FRANCIS LEONARD bought 30,196 shares for $19.11 per share.
Paravasthu Mukund sold 592 shares of NVCR for $10,604 on May 03 ’25. The Chief Operating Officer now owns 83,556 shares after completing the transaction at $17.91 per share. On May 05 ’25, another insider, MUKUND PARAVASTHU, who serves as the Officer of the company, bought 592 shares for $17.91 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 5.25.
Stock Price History:
Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $14.17. The 50-Day Moving Average of the stock is -3.63%, while the 200-Day Moving Average is calculated to be -15.78%.
Shares Statistics:
A total of 111.48M shares are outstanding, with a floating share count of 99.01M. Insiders hold about 11.19% of the company’s shares, while institutions hold 85.15% stake in the company.
Earnings Estimates
The market rating of NovoCure Ltd (NVCR) is currently shaped by the ongoing analysis conducted by 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.37 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.54 and -$1.78 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$1.75, with 7.0 analysts recommending between -$1.38 and -$2.09.
Revenue Estimates
6 analysts predict $153.87M in revenue for the current quarter. It ranges from a high estimate of $156.7M to a low estimate of $150.13M. As of the current estimate, NovoCure Ltd’s year-ago sales were $150.36MFor the next quarter, 6 analysts are estimating revenue of $156.92M. There is a high estimate of $159.2M for the next quarter, whereas the lowest estimate is $153.6M.
A total of 6 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $634.9M, while the lowest revenue estimate was $615.02M, resulting in an average revenue estimate of $626.32M. In the same quarter a year ago, actual revenue was $605.22MBased on 7 analysts’ estimates, the company’s revenue will be $683.22M in the next fiscal year. The high estimate is $711.3M and the low estimate is $668.67M.
